|drug1709||Ivermectin + Placebo Wiki||1.00|
|drug977||Data record Wiki||0.71|
There is one clinical trial.
Burden: Initial outbreak of corona virus disease 2019 (COVID-19) was reported from Wuhan, China in early December 2019.Presently known to be caused by a novel beta-corona virus, named as Severe acute respiratory syndrome corona virus 2 ( SARS-CoV-2). World Health Organization (WHO) declared a pandemic on March. The clinical characteristics of COVID-19 include respiratory symptoms, fever, cough, dyspnoea and pneumonia Infected individuals exhibit: 1. Mostly mild illness (80% +) recover without any treatment (~80%) 2. Moderate illness that needs hospitalization and recovers after standard 3. supportive treatment (~14%) 4. Critical illness (~5%) needs ICU support 5. Death (1-2% ) COVID-19 has now spread >210 countries and territories globally. SARS-CoV-2 is a respiratory virus which spreads primarily through droplets generalized when an infected person coughs or sneezes or through droplets of saliva or discharge from the nose. Symptomatic management remains the mainstay of treatment strategy. Mortality appears to be more common in older individuals and those with co-morbidities, such as chronic lung disease, cardiovascular disease and diabetes. Young people with no comorbidities also appear to be at risk for critical illness including multi-organ failure and death. Seen more in Bangladesh between 21-40 yrs of age. Knowledge Gap: There is no specific treatment against this new virus that WHO has officially declared until now.There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. National Guidelines on Clinical Management of Corona virus Disease 2019 (Covid-19): V 5.0 date 9th April 2020) CDC, DGHS, GoB Thus an RCT is urgently needed in Bangladesh: Based on recent literatures on Rx studies in COVID-19 patients from other countries as well as its availability & affordability of those repurposed medicines
Description: • Presence of virus will be negative on Day 7 detected by RT PCRMeasure: Virological clearance Time: within 7 days after enrollment
Description: • Body temperature will be between 36.1 to 37.2 C by day 7 detected by Infrared thermometerMeasure: Remission of fever Time: within 7 days after enrollment
Description: • Remission of cough: No signs of cough showing respiratory rate within 12-20/ min, on day7Measure: Remission of cough Time: within 7 days after enrollment
Description: Detected SPO2 level <94% on Day 7or before by pulse oxymeterMeasure: Patients requiring oxygen Time: within 7 days after enrollment
Description: Patients who fail to maintain pulse oxymeter detected SpO2 level>93% despite O2 supplementation of 2-6 L/min, on Day 7 or beforeMeasure: Patients failing to maintain SpO2 >93% despite oxygenation Time: within 7 days after enrollment
Description: Any number of days on oxygen support on Day 7 or before recorded in CRFMeasure: Number of days on oxygen support Time: within 7 days after enrollment
Description: Hospital stay ≥7days to ≤14 days as per CRF recordsMeasure: Duration of hospitalization Time: within 14 days after enrollment
Description: Death any time during 14 days of study period from any cause recorded in CRF and Hospital death certificateMeasure: All causes of mortality Time: within 14 days after enrollment
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports